These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 9016768

  • 21. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
    Du K, Nicole P, Couvineau A, Laburthe M.
    Ann N Y Acad Sci; 1998 Dec 11; 865():386-9. PubMed ID: 9928035
    [No Abstract] [Full Text] [Related]

  • 22. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
    Couvineau A, Rouyer-Fessard C, Laburthe M.
    Regul Pept; 2004 Dec 15; 123(1-3):181-5. PubMed ID: 15518910
    [Abstract] [Full Text] [Related]

  • 23. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation.
    Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ.
    J Pharmacol Exp Ther; 2000 Nov 15; 295(2):682-8. PubMed ID: 11046106
    [Abstract] [Full Text] [Related]

  • 24. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding.
    Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M.
    Biochem Biophys Res Commun; 1995 Jun 26; 211(3):901-8. PubMed ID: 7598720
    [Abstract] [Full Text] [Related]

  • 25. Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist.
    Frändberg PA, Doufexis M, Kapas S, Chhajlani V.
    Biochem Biophys Res Commun; 2001 Mar 09; 281(4):851-7. PubMed ID: 11237737
    [Abstract] [Full Text] [Related]

  • 26. Identification of a VIP-specific receptor in guinea pig tenia coli.
    Teng BQ, Grider JR, Murthy KS.
    Am J Physiol Gastrointest Liver Physiol; 2001 Sep 09; 281(3):G718-25. PubMed ID: 11518684
    [Abstract] [Full Text] [Related]

  • 27. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P, Langlet C, Langer I, Gaspard N, Robberecht P.
    Peptides; 2004 Nov 09; 25(11):1943-9. PubMed ID: 15501526
    [Abstract] [Full Text] [Related]

  • 28. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I, Vertongen P, Langer I, Perret J, Robberecht P, Waelbroeck M.
    Biochem J; 2003 Mar 15; 370(Pt 3):1003-9. PubMed ID: 12475394
    [Abstract] [Full Text] [Related]

  • 29. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2001 Aug 15; 133(8):1249-54. PubMed ID: 11498510
    [Abstract] [Full Text] [Related]

  • 30. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S, Kopras E, McMichael M, Bell RH, Ulrich CD.
    Cancer Res; 1997 Apr 15; 57(8):1475-80. PubMed ID: 9108448
    [Abstract] [Full Text] [Related]

  • 31. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P, Vandermeers A, Van Rampelbergh J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Ann N Y Acad Sci; 1998 Dec 11; 865():247-52. PubMed ID: 9928018
    [Abstract] [Full Text] [Related]

  • 32. Constitutive activation of the human VIP1 receptor.
    Gaudin P, Rouyer-Fessard C, Couvineau A, Maoret JJ, Laburthe M.
    Ann N Y Acad Sci; 1998 Dec 11; 865():382-5. PubMed ID: 9928034
    [No Abstract] [Full Text] [Related]

  • 33. Identification of amino acid residues in transmembrane helices VI and VII of the lutropin/choriogonadotropin receptor involved in signaling.
    Fernandez LM, Puett D.
    Biochemistry; 1996 Apr 02; 35(13):3986-93. PubMed ID: 8672431
    [Abstract] [Full Text] [Related]

  • 34. Mutagenesis of N-glycosylation sites in the human VIP 1 receptor.
    Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M.
    Ann N Y Acad Sci; 1996 Dec 26; 805():558-62. PubMed ID: 8993439
    [No Abstract] [Full Text] [Related]

  • 35. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
    Taupenot L, Mahata SK, Wu H, O'Connor DT.
    J Clin Invest; 1998 Feb 15; 101(4):863-76. PubMed ID: 9466982
    [Abstract] [Full Text] [Related]

  • 36. Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding.
    Du K, Couvineau A, Rouyer-Fessard C, Nicole P, Laburthe M.
    J Biol Chem; 2002 Oct 04; 277(40):37016-22. PubMed ID: 12133828
    [Abstract] [Full Text] [Related]

  • 37. Functional roles of conserved transmembrane prolines in the human VPAC(1) receptor.
    Knudsen SM, Tams JW, Fahrenkrug J.
    FEBS Lett; 2001 Aug 17; 503(2-3):126-30. PubMed ID: 11513868
    [Abstract] [Full Text] [Related]

  • 38. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties.
    Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M.
    Eur J Pharmacol; 1996 Apr 29; 302(1-3):207-14. PubMed ID: 8791009
    [Abstract] [Full Text] [Related]

  • 39. The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.
    Wulff B, Møller Knudsen S, Adelhorst K, Fahrenkrug J.
    FEBS Lett; 1997 Aug 25; 413(3):405-8. PubMed ID: 9303545
    [Abstract] [Full Text] [Related]

  • 40. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
    Van Rampelbergh J, Juarranz MG, Perret J, Bondue A, Solano RM, Delporte C, De Neef P, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2000 Jun 25; 130(4):819-26. PubMed ID: 10864888
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.